Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients

Anti-programmed death-1 (PD-1) therapy has been extensively used to treat cancer. Recently, the combination of immunotherapy and anti-angiogenic therapy has emerged as a novel treatment approach. Therefore, we designed a study to evaluate the real-world benefit of the combination of anti-PD-1 and an...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Lupeng, Zhao, Xiao, Shi, Weiwei, Sun, Shengjie, Zhang, Guoqing, Sun, Qiong, Meng, Jing, Xiong, Qi, Qin, Boyu, Jiao, Shunchang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302578/
https://www.ncbi.nlm.nih.gov/pubmed/32541476
http://dx.doi.org/10.1097/MD.0000000000020545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302578/
https://www.ncbi.nlm.nih.gov/pubmed/32541476
http://dx.doi.org/10.1097/MD.0000000000020545

Ejemplares similares